BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 15, 2009
View Archived Issues
Santen describes novel glucocorticoid receptor ligands for metabolic disorders, among others
Read More
Ipsen provides R&D pipeline update
Read More
Qnexa treatment improves glucose control in obese nondiabetic subjects
Read More
EpiCept to focus on Ceplene and discontinue drug discovery operations
Read More
MAP Pharmaceuticals presents update on phase III clinical trials of UDB and MAP-0004
Read More
ARYx reports results related to washout period from phase IIb trial of ATI-2042
Read More
Repros reports results from phase II trial of Proellex in endometriosis
Read More
Genta updates progress of phase III trial of Genasense in advanced melanoma
Read More
ASA-404 enters pivotal phase III second-line lung cancer trial
Read More
Cyclacel begins phase II sapacitabine trial in previously treated NSCLC patients
Read More
Idenix initiates proof-of-concept study of IDX-184 for hepatitis C virus
Read More
Lexicon initiates phase II LX-1031 trial in patients with irritable bowel syndrome
Read More
Neurobiological Technologies suspends Viprinex development
Read More
Protox commences placebo-controlled phase II BPH study
Read More
New gamma-secretase modulators reported in recent Schering-Plough patent
Read More
MacuCLEAR and Mystic collaborate on macular degeneration phase I/II trial
Read More
Merck & Co. discloses novel orexin receptor antagonists for insomnia
Read More
Novel modulators of sodium and/or calcium channels under development at Newron
Read More
First patient dosed in phase II NKTR-102 trial in ovarian cancer
Read More
Genta commences new trial for oral tesetaxel
Read More
e-Therapeutics reports positive phase IIa findings for antidepressant ETS-6103
Read More
Acorda provides 2009 pipeline update
Read More
Sunesis provides clinical update on voreloxin
Read More
Phosphatase inhibition may improve proteasome inhibitor treatment of leukemia
Read More
Targeting peptide enhances utility of liposomal anticancer agents in lung cancer xenografts
Read More
